Your browser doesn't support javascript.
loading
Medulloblastomas with ELP1 pathogenic variants: A weakly penetrant syndrome with a restricted spectrum in a limited age window.
Guerrini-Rousseau, Léa; Masliah-Planchon, Julien; Filser, Mathilde; Tauziède-Espariat, Arnault; Entz-Werle, Natacha; Maugard, Christine M; Hopman, Saskia M J; Torrejon, Jacob; Gauthier-Villars, Marion; Simaga, Fatoumata; Blauwblomme, Thomas; Beccaria, Kevin; Rouleau, Etienne; Dimaria, Marina; Grill, Jacques; Abbou, Samuel; Claret, Béatrice; Brugières, Laurence; Doz, François; Bouchoucha, Yassine; Faure-Conter, Cécile; Bonadona, Valerie; Mansuy, Ludovic; de Carli, Emilie; Ingster, Olivier; Legrand, Clémentine; Pagnier, Anne; Berthet, Pascaline; Bodet, Damien; Julia, Sophie; Bertozzi, Anne-Isabelle; Wilems, Marjolaine; Maurage, Claude-Alain; Delattre, Olivier; Ayrault, Olivier; Dufour, Christelle; Bourdeaut, Franck.
Affiliation
  • Guerrini-Rousseau L; Molecular Predictors and New Targets in Oncology, Inserm U981 Team "Genomics and Oncogenesis of Pediatric Brain Tumors," Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Masliah-Planchon J; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Filser M; Department of Pathology and Diagnostic, Prognostic and Theranostic Medicine, Somatic Genetic Unit, Institut Curie, Paris Sciences Lettres Research University, Paris, France.
  • Tauziède-Espariat A; Department of Pathology and Diagnostic, Prognostic and Theranostic Medicine, Somatic Genetic Unit, Institut Curie, Paris Sciences Lettres Research University, Paris, France.
  • Entz-Werle N; Department of Neuropathology, Sainte Anne Hospital, Paris, France.
  • Maugard CM; Pediatric Hematology and Oncology Department, Strasbourg University Hospital, University of Strasbourg, Strasbourg, France.
  • Hopman SMJ; Department of Clinical Genetics, Strasbourg University Hospital, Strasbourg, France.
  • Torrejon J; Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Gauthier-Villars M; Université Paris Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, France.
  • Simaga F; Institut Curie, Paris Sciences Lettres Research University, CNRS UMR, INSERM, Orsay, France.
  • Blauwblomme T; Department of Genetics, Institut Curie, Paris Sciences Lettres Research University, Paris, France.
  • Beccaria K; Department of Genetics, Institut Curie, Paris Sciences Lettres Research University, Paris, France.
  • Rouleau E; Necker-Enfants Malades University Hospital, Department of Pediatric Neurosurgery, Paris-Cité University, Paris, France.
  • Dimaria M; Necker-Enfants Malades University Hospital, Department of Pediatric Neurosurgery, Paris-Cité University, Paris, France.
  • Grill J; Cancer Genetics Unit, Department of Biology and Pathology, Institut Gustave Roussy, Villejuif, France.
  • Abbou S; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Claret B; Molecular Predictors and New Targets in Oncology, Inserm U981 Team "Genomics and Oncogenesis of Pediatric Brain Tumors," Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Brugières L; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Doz F; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Bouchoucha Y; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy, Villejuif, France.
  • Faure-Conter C; Psycho-Oncology Unit, Interdisciplinary Department of Supportive Care, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Bonadona V; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Mansuy L; Université Paris Cité, SIREDO Pediatric Cancer Center, Institut Curie, Paris, France.
  • de Carli E; SIREDO Center (Care, Innovation Research in Pediatric, Adolescent and Young Adult Oncology), Institut Curie, Paris, France.
  • Ingster O; SIREDO Center (Care, Innovation Research in Pediatric, Adolescent and Young Adult Oncology), Institut Curie, Paris, France.
  • Legrand C; Pediatric Hematology and Oncology Institut, Centre Léon Berard, Lyon, France.
  • Pagnier A; Clinical Oncogenetics Unit, Department of Prevention and Public Health, Centre Léon Bérard, Lyon, France.
  • Berthet P; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Nancy, Vandœuvre-lès-Nancy, France.
  • Bodet D; Pediatric Hematology and Oncology Department, Angers University Hospital, Nancy, France.
  • Julia S; Department of Genetics, Angers University Hospital, Angers, France.
  • Bertozzi AI; Department of Genetics, Grenoble University Hospital, Grenoble, France.
  • Wilems M; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Grenoble, Grenoble, France.
  • Maurage CA; Department of Genetics, Centre François Baclesse, Caen, France.
  • Delattre O; Pediatric Hematology and Oncology Department, Caen University Hospital, Caen, France.
  • Ayrault O; Department of Genetics, Toulouse University Hospital, Toulouse, France.
  • Dufour C; Pediatric Hematology and Oncology Department, Toulouse University Hospital, Toulouse, France.
  • Bourdeaut F; Department of Medical Genetics, Montpellier University Hospital, Institute for Neurosciences of Montpellier, Univ Montpellier, INSERM, Montpellier, France.
Neurooncol Adv ; 6(1): vdae075, 2024.
Article in En | MEDLINE | ID: mdl-38962751
ABSTRACT

Background:

ELP1 pathogenic variants (PV) have been recently identified as the most frequent variants predisposing to Sonic Hedgehog (SHH) medulloblastomas (MB); however, guidelines are still lacking for genetic counseling in this new syndrome.

Methods:

We retrospectively reviewed clinical and genetic data of a French series of 29 ELP1-mutated MB.

Results:

All patients developed SHH-MB, with a biallelic inactivation of PTCH1 found in 24 tumors. Other recurrent alterations encompassed the TP53 pathway and activation of MYCN/MYCL signaling. The median age at diagnosis was 7.3 years (range 3-14). ELP1-mutated MB behave as sporadic cases, with similar distribution within clinical and molecular risk groups and similar outcomes (5 y - OS = 86%); no unusual side effect of treatments was noticed. Remarkably, a germline ELP1 PV was identified in all patients with available constitutional DNA (n = 26); moreover, all tested familial trio (n = 11) revealed that the PVs were inherited. Two of the 26 index cases from the French series had a family history of MB; pedigrees from these patients and from 1 additional Dutch family suggested a weak penetrance. Apart from MB, no cancer was associated with ELP1 PVs; second tumors reported in 4 patients occurred within the irradiation fields, in the usual time-lapse for expected radiotherapy-induced neoplasms.

Conclusions:

The low penetrance, the "at risk' age window limited to childhood and the narrow tumor spectrum, question the actual benefit of genetic screening in these patients and their family. Our results suggest restricting ELP1 germline sequencing to patients with SHH-MB, depending on the parents" request.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurooncol Adv Year: 2024 Document type: Article Affiliation country: Francia

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurooncol Adv Year: 2024 Document type: Article Affiliation country: Francia
...